Trial Profile
CNS Unmet Medical Need in Mucopolysaccharidosis: A Phase 2 Safety and Pharmacokinetics Study of Ataluren (COMPASS)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 13 Oct 2020
Price :
$35
*
At a glance
- Drugs Ataluren (Primary)
- Indications Mucopolysaccharidosis I
- Focus Adverse reactions; Pharmacokinetics; Proof of concept
- Acronyms Compass
- Sponsors PTC Therapeutics
- 09 Oct 2020 Status changed from recruiting to discontinued.
- 13 Sep 2017 Trial has been completed in Germany (End date: 2017-07-20)
- 17 May 2016 Status changed from not yet recruiting to recruiting.